Investment Rating - The report maintains an "Accumulate" rating for the company [6] Core Views - The company achieved a revenue of 439 million RMB in H1 2025, representing a year-on-year growth of 11.33%, with a net profit attributable to shareholders of 30 million RMB, compared to 11 million RMB in the same period of 2024 [1][4] - In Q2 2025, the company reported a revenue of 232 million RMB, a year-on-year increase of 16.32%, and a net profit of 15 million RMB, recovering from a loss of 2 million RMB in Q2 2024 [1] - The company is focusing on enhancing product development and has successfully implemented several core business system projects in hospitals, contributing to improved operational quality [1][3] Summary by Sections Financial Performance - The gross margin for H1 2025 was 43.98%, an increase of 4.77 percentage points year-on-year [2] - The company's revenue from the medical insurance sector was 238 million RMB, up 2.63% year-on-year, with a gross margin of 48.12%, an increase of 4.54 percentage points [2] - The digital government revenue reached 147 million RMB, growing by 6.94% year-on-year, with a gross margin of 37.89%, up 6.86 percentage points [2] - The smart city revenue surged by 409.88% year-on-year to 52 million RMB, although the gross margin slightly decreased by 1.15 percentage points [2] Business Strategy - The company is deepening its focus on the "application + technology" data business layout, particularly in public data for governance and healthcare [3] - It has developed a comprehensive platform for data governance and synchronization, supporting various sectors including healthcare and smart cities [3] - The company is actively promoting AI product implementation in the medical insurance sector, with its services covering over 2,800 hospitals across 26 provinces [3] Profit Forecast and Valuation - The report maintains profit forecasts, expecting net profits of 105 million RMB, 141 million RMB, and 180 million RMB for 2025, 2026, and 2027 respectively [4] - The target price for the company is set at 25.90 RMB, based on a 75 times PE ratio for 2026, reflecting the broad commercial potential of its medical insurance data [4][8]